• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

作者信息

Pratt Guy, Yap Christina, Oldreive Ceri, Slade Daniel, Bishop Rebecca, Griffiths Mike, Dyer Martin J S, Fegan Chris, Oscier David, Pettitt Andrew, Matutes Estella, Devereux Stephen, Allsup David, Bloor Adrian, Hillmen Peter, Follows George, Rule Simon, Moss Paul, Stankovic Tatjana

机构信息

University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.

出版信息

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23.

DOI:10.1111/bjh.14793
PMID:28643365
Abstract
摘要

相似文献

1
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.一项针对复发的慢性淋巴细胞白血病、T 前淋巴细胞白血病或套细胞淋巴瘤患者的 PARP 抑制剂奥拉帕利的多中心 I 期试验。
Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23.
2
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.聚腺苷二磷酸核糖聚合酶抑制剂奥拉帕尼在体外和体内诱导 ATM 缺陷型淋巴肿瘤细胞的显著杀伤。
Blood. 2010 Nov 25;116(22):4578-87. doi: 10.1182/blood-2010-01-265769. Epub 2010 Aug 25.
3
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).在伴有 DNA 修复缺陷的一线转移性去势抵抗性前列腺癌（BRCAAway）中，阿比特龙、奥拉帕利或阿比特龙+奥拉帕利。
Clin Cancer Res. 2024 Oct 1;30(19):4318-4328. doi: 10.1158/1078-0432.CCR-24-1402.
4
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.奥拉帕利治疗携带 DNA 损伤修复基因缺陷的儿童肿瘤：NCI-COG 儿科 MATCH 试验的臂 H。
Oncologist. 2024 Jul 5;29(7):638-e952. doi: 10.1093/oncolo/oyae096.
5
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).Ceralasertib 介导的 ATR 抑制与奥拉帕利联合用于存在 DNA 损伤反应和修复改变的晚期癌症（奥拉帕利联合治疗）。
JCO Precis Oncol. 2021 Sep 7;5. doi: 10.1200/PO.20.00439. eCollection 2021.
6
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
7
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.胚系BRCA1/2突变的晚期卵巢癌患者对PARP抑制剂奥拉帕尼抗肿瘤反应的基线临床预测指标。
Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
8
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.Umbralisib联合伊布替尼治疗复发或难治性慢性淋巴细胞白血病或套细胞淋巴瘤患者：一项多中心1-1b期研究
Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.
9
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline mutations: OPINION Phase IIIb study design.奥拉帕利单药维持治疗无胚系突变的铂敏感复发性卵巢癌：IIIb 期研究设计。
Future Oncol. 2019 Nov;15(32):3651-3663. doi: 10.2217/fon-2019-0343. Epub 2019 Sep 25.
10
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.同时存在 ATM 和 p53 突变的套细胞淋巴瘤中，聚腺苷二磷酸核糖聚合酶抑制剂的细胞毒性增强。
EMBO Mol Med. 2012 Jun;4(6):515-27. doi: 10.1002/emmm.201200229. Epub 2012 Mar 13.

引用本文的文献

1
Therapeutic Targeting of DNA Damage Response Pathways in - and -Mutated Tumors.针对[具体肿瘤名称]和[具体突变类型]突变肿瘤中DNA损伤反应通路的治疗靶向
Brain Tumor Res Treat. 2025 Jul;13(3):73-80. doi: 10.14791/btrt.2025.0017.
2
Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.慢性淋巴细胞白血病中基因畸变与信号通路相互作用的见解：从发病机制到治疗策略
Biomark Res. 2024 Dec 28;12(1):162. doi: 10.1186/s40364-024-00710-w.
3
Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
妇科恶性肿瘤治疗药物的眼部不良反应。
Gynecol Oncol. 2024 Sep;188:147-157. doi: 10.1016/j.ygyno.2024.06.003. Epub 2024 Jul 4.
4
Targeted Therapies in the Treatment of Mantle Cell Lymphoma.套细胞淋巴瘤治疗中的靶向疗法
Cancers (Basel). 2024 May 20;16(10):1937. doi: 10.3390/cancers16101937.
5
Targeting the DNA damage response in hematological malignancies.针对血液系统恶性肿瘤中的DNA损伤反应
Front Oncol. 2024 Jan 29;14:1307839. doi: 10.3389/fonc.2024.1307839. eCollection 2024.
6
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.T 细胞前淋巴细胞白血病：诊断、发病机制与治疗。
Int J Mol Sci. 2023 Jul 28;24(15):12106. doi: 10.3390/ijms241512106.
7
SF3B1-mutant cells succumb to replication stress under PARP inhibition.SF3B1 突变细胞在 PARP 抑制下会因复制应激而死亡。
Nat Genet. 2023 Aug;55(8):1265-1266. doi: 10.1038/s41588-023-01461-4.
8
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.SF3B1 热点突变通过引发有缺陷的复制应激反应赋予对 PARP 抑制的敏感性。
Nat Genet. 2023 Aug;55(8):1311-1323. doi: 10.1038/s41588-023-01460-5. Epub 2023 Jul 31.
9
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma.p53直接下调CDC20的表达，从而在套细胞淋巴瘤中发挥抗肿瘤活性。
Exp Hematol Oncol. 2023 Mar 7;12(1):28. doi: 10.1186/s40164-023-00381-7.
10
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.对PARP抑制剂诱导的合成致死的固有和获得性抗性
Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.